UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 463

Sortiert nach

Multicenter, Phase II Study of Decitabine for the First-Line Treatment of Older Patients With Acute Myeloid Leukemia

Journal of clinical oncology, 2010-02, Vol.28 (4), p.556-561

2010

Link zum Volltext

Verfügbarkeit prüfen

Phase 2b study of 2 dosing regimens of quizartinib monotherapy in FLT3-ITD–mutated, relapsed or refractory AML

Blood, 2018-08, Vol.132 (6), p.598-607

2018

Link zum Volltext

Verfügbarkeit prüfen

Phase IIB Trial of Oral Midostaurin (PKC412), the FMS-Like Tyrosine Kinase 3 Receptor (FLT3) and Multi-Targeted Kinase Inhibitor, in Patients With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome With Either Wild-Type or Mutated FLT3

Journal of clinical oncology, 2010-10, Vol.28 (28), p.4339-4345

2010

Link zum Volltext

Verfügbarkeit prüfen

Hematopoietic stem cell transplantation in primary central nervous system lymphoma: a review of the literature

International journal of hematology, 2019-03, Vol.109 (3), p.260-277

2019

Link zum Volltext

Verfügbarkeit prüfen

Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study

The lancet oncology, 2015-09, Vol.16 (9), p.1025-1036

2015

Link zum Volltext

Verfügbarkeit prüfen

Emerging strategies for high-risk and relapsed/refractory acute myeloid leukemia: Novel agents and approaches currently in clinical trials

Blood reviews, 2015-01, Vol.29 (1), p.1-9

2015

Link zum Volltext

Verfügbarkeit prüfen

High-risk acute myelogenous leukemia: treatment today ... and tomorrow

Hematology, 2013, Vol.2013 (1), p.201-208

Schiller, Gary J

2013

Link zum Volltext

Verfügbarkeit prüfen

Control of Plasma Uric Acid in Adults at Risk for Tumor Lysis Syndrome: Efficacy and Safety of Rasburicase Alone and Rasburicase Followed by Allopurinol Compared With Allopurinol Alone—Results of a Multicenter Phase III Study

Journal of clinical oncology, 2010-09, Vol.28 (27), p.4207-4213

2010

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of once weekly selinexor 40 mg versus 60 mg with pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma

Frontiers in oncology, 2024-05, Vol.14, p.1352281-1352281

2024

Link zum Volltext

Verfügbarkeit prüfen

High-Dose Cytarabine (HD araC) in the Treatment of Leukemias: a Review

Current hematologic malignancy reports, 2013-06, Vol.8 (2), p.141-148

2013

Link zum Volltext

Verfügbarkeit prüfen

Phase I/II Trial of AEG35156 X-Linked Inhibitor of Apoptosis Protein Antisense Oligonucleotide Combined With Idarubicin and Cytarabine in Patients With Relapsed or Primary Refractory Acute Myeloid Leukemia

Journal of clinical oncology, 2009-10, Vol.27 (28), p.4741-4746

2009

Link zum Volltext

Verfügbarkeit prüfen

CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia

Journal of clinical oncology, 2018-09, Vol.36 (26), p.2684-2692

2018

Link zum Volltext

Verfügbarkeit prüfen

Considerations regarding maintenance therapy for acute myeloid leukemia in remission

Expert review of anticancer therapy, 2024, Vol.24 (1-2), p.15-20

2024

Link zum Volltext

Verfügbarkeit prüfen

Single-Agent Laromustine, A Novel Alkylating Agent, Has Significant Activity in Older Patients With Previously Untreated Poor-Risk Acute Myeloid Leukemia

Journal of clinical oncology, 2010-02, Vol.28 (5), p.815-821

2010

Link zum Volltext

Verfügbarkeit prüfen

Effectiveness of Single-Fraction, Low-Dose, Bilateral Whole Lung Radiation Therapy for Diffuse Alveolar Hemorrhage Secondary to Extramedullary Hematopoiesis: A Case Report and Review of the Literature

Advances in radiation oncology, 2024-07, Vol.9 (7), p.101506, Article 101506

2024

Link zum Volltext

Verfügbarkeit prüfen

A Phase 1 study of intravenous infusions of tigecycline in patients with acute myeloid leukemia

Cancer medicine (Malden, MA), 2016-11, Vol.5 (11), p.3031-3040

2016

Link zum Volltext

Verfügbarkeit prüfen

Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia

The New England journal of medicine, 2018-04, Vol.378 (16), p.1479-1493

2018

Link zum Volltext

Verfügbarkeit prüfen

An exploratory phase 2 study of investigational Aurora A kinase inhibitor alisertib (MLN8237) in acute myelogenous leukemia and myelodysplastic syndromes

Leukemia research reports, 2014, Vol.3 (2), p.58-61

2014

Link zum Volltext

Verfügbarkeit prüfen

Follow-up of patients with R/R FLT3-mutation–positive AML treated with gilteritinib in the phase 3 ADMIRAL trial

Blood, 2022-06, Vol.139 (23), p.3366-3375

2022

Link zum Volltext

Verfügbarkeit prüfen

Fosmanogepix Therapy of Disseminated Fusarium Infection

Clinical infectious diseases, 2023-09, Vol.77 (6), p.848-850

2023

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 463

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(418)
Mit Volltextzugriff
(448)

Publikationsform

Sprache

Englisch
(462)
Japanisch
(32)
Spanisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(163)
Life Sciences & Biomedicine
(161)
Humans
(139)
Hematology
(90)
Male
(78)
Female
(77)
Adult
(70)
Middle Aged
(67)
Biological And Medical Sciences
(64)
Medical Sciences
(63)
Aged
(56)
Oncology
(53)
Treatment Outcome
(33)
Adolescent
(32)
Immunology
(32)
Leukemia, Myeloid, Acute - Drug Therapy
(27)
Transplantation
(25)
Animals
(24)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(21)
General & Internal Medicine
(21)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Multicenter, Phase II Study of Decitabine for the First-Line Treatment of Older Patients With Acute Myeloid Leukemia

Phase 2b study of 2 dosing regimens of quizartinib monotherapy in FLT3-ITD–mutated, relapsed or refractory AML

Phase IIB Trial of Oral Midostaurin (PKC412), the FMS-Like Tyrosine Kinase 3 Receptor (FLT3) and Multi-Targeted Kinase Inhibitor, in Patients With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome With Either Wild-Type or Mutated FLT3

Omidubicel vs standard myeloablative umbilical cord blood transplantation: results of a phase 3 randomized study

Hematopoietic stem cell transplantation in primary central nervous system lymphoma: a review of the literature

Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study

Emerging strategies for high-risk and relapsed/refractory acute myeloid leukemia: Novel agents and approaches currently in clinical trials

High-risk acute myelogenous leukemia: treatment today ... and tomorrow

Control of Plasma Uric Acid in Adults at Risk for Tumor Lysis Syndrome: Efficacy and Safety of Rasburicase Alone and Rasburicase Followed by Allopurinol Compared With Allopurinol Alone—Results of a Multicenter Phase III Study

Efficacy and safety of once weekly selinexor 40 mg versus 60 mg with pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma

High-Dose Cytarabine (HD araC) in the Treatment of Leukemias: a Review

Phase I/II Trial of AEG35156 X-Linked Inhibitor of Apoptosis Protein Antisense Oligonucleotide Combined With Idarubicin and Cytarabine in Patients With Relapsed or Primary Refractory Acute Myeloid Leukemia

Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain

CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia

Considerations regarding maintenance therapy for acute myeloid leukemia in remission

Phase 3 results for vosaroxin/cytarabine in the subset of patients ≥60 years old with refractory/early relapsed acute myeloid leukemia

KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study

Single-Agent Laromustine, A Novel Alkylating Agent, Has Significant Activity in Older Patients With Previously Untreated Poor-Risk Acute Myeloid Leukemia

Effectiveness of Single-Fraction, Low-Dose, Bilateral Whole Lung Radiation Therapy for Diffuse Alveolar Hemorrhage Secondary to Extramedullary Hematopoiesis: A Case Report and Review of the Literature

A Phase 1 study of intravenous infusions of tigecycline in patients with acute myeloid leukemia

Selinexor‐based regimens in patients with multiple myeloma after prior anti‐B‐cell maturation antigen treatment

Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia

An exploratory phase 2 study of investigational Aurora A kinase inhibitor alisertib (MLN8237) in acute myelogenous leukemia and myelodysplastic syndromes

Follow-up of patients with R/R FLT3-mutation–positive AML treated with gilteritinib in the phase 3 ADMIRAL trial

Fosmanogepix Therapy of Disseminated Fusarium Infection

Suchergebnisse filtern